The industry has given big bucks to U.S. Rep. Greg Walden, who chairs a powerful congressional committee, but has ignored Rep. Peter DeFazio, who is not on any committees that influence drug legislation.
October 29, 2018
Image
CC BY SA-2.0
Oregon’s congressional delegation includes members who are among the most courted by the nation’s pharmaceutical industry, and those who are among
